compound 2 for Search Results


dl propargylglycine  (Chem Impex International)
95
Chem Impex International dl propargylglycine
A schematic presentation of diabetes induction, pharmacologic intervention, and the biochemical and molecular studies conducted to investigate the glycemic and cardiovascular effects of moxonidine (2 or 6 mg/kg/day, p.o) in diabetic male Wistar rats in the absence or presence of H2S-synthesis inhibitor, <t>DL-propargylglycine</t> (37.5 mg/kg/day, i.p) during the last 3 weeks of the experiment. STZ, streptozotocin; BW, body weight; BGL, blood glucose level; OGTT, oral glucose tolerance test.
Dl Propargylglycine, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dl propargylglycine/product/Chem Impex International
Average 95 stars, based on 1 article reviews
dl propargylglycine - by Bioz Stars, 2026-06
95/100 stars
  Buy from Supplier
di tert butyl dicarbonate  (Chem Impex International)
95
Chem Impex International di tert butyl dicarbonate
A schematic presentation of diabetes induction, pharmacologic intervention, and the biochemical and molecular studies conducted to investigate the glycemic and cardiovascular effects of moxonidine (2 or 6 mg/kg/day, p.o) in diabetic male Wistar rats in the absence or presence of H2S-synthesis inhibitor, <t>DL-propargylglycine</t> (37.5 mg/kg/day, i.p) during the last 3 weeks of the experiment. STZ, streptozotocin; BW, body weight; BGL, blood glucose level; OGTT, oral glucose tolerance test.
Di Tert Butyl Dicarbonate, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/di tert butyl dicarbonate/product/Chem Impex International
Average 95 stars, based on 1 article reviews
di tert butyl dicarbonate - by Bioz Stars, 2026-06
95/100 stars
  Buy from Supplier
aminomethyl 2 methylpyrimidin 4 amine berkshire united kingdom comparative compound  (Biosynth Carbosynth)
99
Biosynth Carbosynth aminomethyl 2 methylpyrimidin 4 amine berkshire united kingdom comparative compound
A schematic presentation of diabetes induction, pharmacologic intervention, and the biochemical and molecular studies conducted to investigate the glycemic and cardiovascular effects of moxonidine (2 or 6 mg/kg/day, p.o) in diabetic male Wistar rats in the absence or presence of H2S-synthesis inhibitor, <t>DL-propargylglycine</t> (37.5 mg/kg/day, i.p) during the last 3 weeks of the experiment. STZ, streptozotocin; BW, body weight; BGL, blood glucose level; OGTT, oral glucose tolerance test.
Aminomethyl 2 Methylpyrimidin 4 Amine Berkshire United Kingdom Comparative Compound, supplied by Biosynth Carbosynth, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aminomethyl 2 methylpyrimidin 4 amine berkshire united kingdom comparative compound/product/Biosynth Carbosynth
Average 99 stars, based on 1 article reviews
aminomethyl 2 methylpyrimidin 4 amine berkshire united kingdom comparative compound - by Bioz Stars, 2026-06
99/100 stars
  Buy from Supplier
compound 1  (Chem Impex International)
95
Chem Impex International compound 1
A schematic presentation of diabetes induction, pharmacologic intervention, and the biochemical and molecular studies conducted to investigate the glycemic and cardiovascular effects of moxonidine (2 or 6 mg/kg/day, p.o) in diabetic male Wistar rats in the absence or presence of H2S-synthesis inhibitor, <t>DL-propargylglycine</t> (37.5 mg/kg/day, i.p) during the last 3 weeks of the experiment. STZ, streptozotocin; BW, body weight; BGL, blood glucose level; OGTT, oral glucose tolerance test.
Compound 1, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/compound 1/product/Chem Impex International
Average 95 stars, based on 1 article reviews
compound 1 - by Bioz Stars, 2026-06
95/100 stars
  Buy from Supplier
benzaldehyde(compound 2)  (FUJIFILM)
90
FUJIFILM benzaldehyde(compound 2)
A schematic presentation of diabetes induction, pharmacologic intervention, and the biochemical and molecular studies conducted to investigate the glycemic and cardiovascular effects of moxonidine (2 or 6 mg/kg/day, p.o) in diabetic male Wistar rats in the absence or presence of H2S-synthesis inhibitor, <t>DL-propargylglycine</t> (37.5 mg/kg/day, i.p) during the last 3 weeks of the experiment. STZ, streptozotocin; BW, body weight; BGL, blood glucose level; OGTT, oral glucose tolerance test.
Benzaldehyde(compound 2), supplied by FUJIFILM, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/benzaldehyde(compound 2)/product/FUJIFILM
Average 90 stars, based on 1 article reviews
benzaldehyde(compound 2) - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
compound ii  (Schmid GmbH)
90
Schmid GmbH compound ii
A schematic presentation of diabetes induction, pharmacologic intervention, and the biochemical and molecular studies conducted to investigate the glycemic and cardiovascular effects of moxonidine (2 or 6 mg/kg/day, p.o) in diabetic male Wistar rats in the absence or presence of H2S-synthesis inhibitor, <t>DL-propargylglycine</t> (37.5 mg/kg/day, i.p) during the last 3 weeks of the experiment. STZ, streptozotocin; BW, body weight; BGL, blood glucose level; OGTT, oral glucose tolerance test.
Compound Ii, supplied by Schmid GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/compound ii/product/Schmid GmbH
Average 90 stars, based on 1 article reviews
compound ii - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
compound 2 4,4′-thiobis(3-methylphenol)  (TimTec LLC)
90
TimTec LLC compound 2 4,4′-thiobis(3-methylphenol)
A schematic presentation of diabetes induction, pharmacologic intervention, and the biochemical and molecular studies conducted to investigate the glycemic and cardiovascular effects of moxonidine (2 or 6 mg/kg/day, p.o) in diabetic male Wistar rats in the absence or presence of H2S-synthesis inhibitor, <t>DL-propargylglycine</t> (37.5 mg/kg/day, i.p) during the last 3 weeks of the experiment. STZ, streptozotocin; BW, body weight; BGL, blood glucose level; OGTT, oral glucose tolerance test.
Compound 2 4,4′ Thiobis(3 Methylphenol), supplied by TimTec LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/compound 2 4,4′-thiobis(3-methylphenol)/product/TimTec LLC
Average 90 stars, based on 1 article reviews
compound 2 4,4′-thiobis(3-methylphenol) - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
compound a  (Muegge GmbH)
90
Muegge GmbH compound a
A schematic presentation of diabetes induction, pharmacologic intervention, and the biochemical and molecular studies conducted to investigate the glycemic and cardiovascular effects of moxonidine (2 or 6 mg/kg/day, p.o) in diabetic male Wistar rats in the absence or presence of H2S-synthesis inhibitor, <t>DL-propargylglycine</t> (37.5 mg/kg/day, i.p) during the last 3 weeks of the experiment. STZ, streptozotocin; BW, body weight; BGL, blood glucose level; OGTT, oral glucose tolerance test.
Compound A, supplied by Muegge GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/compound a/product/Muegge GmbH
Average 90 stars, based on 1 article reviews
compound a - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
compounds 71, 79, and 87  (WuXi AppTec)
90
WuXi AppTec compounds 71, 79, and 87
A schematic presentation of diabetes induction, pharmacologic intervention, and the biochemical and molecular studies conducted to investigate the glycemic and cardiovascular effects of moxonidine (2 or 6 mg/kg/day, p.o) in diabetic male Wistar rats in the absence or presence of H2S-synthesis inhibitor, <t>DL-propargylglycine</t> (37.5 mg/kg/day, i.p) during the last 3 weeks of the experiment. STZ, streptozotocin; BW, body weight; BGL, blood glucose level; OGTT, oral glucose tolerance test.
Compounds 71, 79, And 87, supplied by WuXi AppTec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/compounds 71, 79, and 87/product/WuXi AppTec
Average 90 stars, based on 1 article reviews
compounds 71, 79, and 87 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
compound 2  (AstraZeneca ltd)
90
AstraZeneca ltd compound 2
A schematic presentation of diabetes induction, pharmacologic intervention, and the biochemical and molecular studies conducted to investigate the glycemic and cardiovascular effects of moxonidine (2 or 6 mg/kg/day, p.o) in diabetic male Wistar rats in the absence or presence of H2S-synthesis inhibitor, <t>DL-propargylglycine</t> (37.5 mg/kg/day, i.p) during the last 3 weeks of the experiment. STZ, streptozotocin; BW, body weight; BGL, blood glucose level; OGTT, oral glucose tolerance test.
Compound 2, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/compound 2/product/AstraZeneca ltd
Average 90 stars, based on 1 article reviews
compound 2 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
compound 1  (AUTODOCK GmbH)
90
AUTODOCK GmbH compound 1
A schematic presentation of diabetes induction, pharmacologic intervention, and the biochemical and molecular studies conducted to investigate the glycemic and cardiovascular effects of moxonidine (2 or 6 mg/kg/day, p.o) in diabetic male Wistar rats in the absence or presence of H2S-synthesis inhibitor, <t>DL-propargylglycine</t> (37.5 mg/kg/day, i.p) during the last 3 weeks of the experiment. STZ, streptozotocin; BW, body weight; BGL, blood glucose level; OGTT, oral glucose tolerance test.
Compound 1, supplied by AUTODOCK GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/compound 1/product/AUTODOCK GmbH
Average 90 stars, based on 1 article reviews
compound 1 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
compound 2  (AstaTech Inc)
90
AstaTech Inc compound 2
A schematic presentation of diabetes induction, pharmacologic intervention, and the biochemical and molecular studies conducted to investigate the glycemic and cardiovascular effects of moxonidine (2 or 6 mg/kg/day, p.o) in diabetic male Wistar rats in the absence or presence of H2S-synthesis inhibitor, <t>DL-propargylglycine</t> (37.5 mg/kg/day, i.p) during the last 3 weeks of the experiment. STZ, streptozotocin; BW, body weight; BGL, blood glucose level; OGTT, oral glucose tolerance test.
Compound 2, supplied by AstaTech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/compound 2/product/AstaTech Inc
Average 90 stars, based on 1 article reviews
compound 2 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

Image Search Results


A schematic presentation of diabetes induction, pharmacologic intervention, and the biochemical and molecular studies conducted to investigate the glycemic and cardiovascular effects of moxonidine (2 or 6 mg/kg/day, p.o) in diabetic male Wistar rats in the absence or presence of H2S-synthesis inhibitor, DL-propargylglycine (37.5 mg/kg/day, i.p) during the last 3 weeks of the experiment. STZ, streptozotocin; BW, body weight; BGL, blood glucose level; OGTT, oral glucose tolerance test.

Journal: European journal of pharmacology

Article Title: Cystathionine-γ lyase-derived hydrogen sulfide mediates the cardiovascular protective effects of moxonidine in diabetic rats

doi: 10.1016/j.ejphar.2016.04.054

Figure Lengend Snippet: A schematic presentation of diabetes induction, pharmacologic intervention, and the biochemical and molecular studies conducted to investigate the glycemic and cardiovascular effects of moxonidine (2 or 6 mg/kg/day, p.o) in diabetic male Wistar rats in the absence or presence of H2S-synthesis inhibitor, DL-propargylglycine (37.5 mg/kg/day, i.p) during the last 3 weeks of the experiment. STZ, streptozotocin; BW, body weight; BGL, blood glucose level; OGTT, oral glucose tolerance test.

Article Snippet: Drugs and Chemicals Moxonidine (American Custom Chemicals Corp., San Diego, CA), DL-propargylglycine (Chem-Impex International Inc., Wood Dale, IL), N,N dimethyl P-phenylene diamine sulfate (Acros Organics “Thermo Fischer Scientific”, Bridgewater, NJ), TEMED (Thermo scientific, Rockford, IL), Acrylamide 40% solution (Fischer Scientific, Pittsburg, PA), ammonium persulfate (J.T Baker, Center Valley, PA), heparin (Elkins Sinn Inc., Cherry Hill, NJ) and sterile saline (B. Braun Medical Inc., Bethlehem, PA) were purchased from commercial vendors.

Techniques:

Effects of 3-week treatment with moxonidine (2 or 6 mg/kg/day; gavage), starting 4 week following diabetes induction, on heart weight (HW), body weight (BW) and HW/BW ratio “index of hypertrophy” in STZ diabetic male Wistar rats. Shown also are the effects of DL-propargylglycine alone in non-diabetic and diabetic rats, and in combination with moxonidine (6 mg/kg/day) in diabetic rats.

Journal: European journal of pharmacology

Article Title: Cystathionine-γ lyase-derived hydrogen sulfide mediates the cardiovascular protective effects of moxonidine in diabetic rats

doi: 10.1016/j.ejphar.2016.04.054

Figure Lengend Snippet: Effects of 3-week treatment with moxonidine (2 or 6 mg/kg/day; gavage), starting 4 week following diabetes induction, on heart weight (HW), body weight (BW) and HW/BW ratio “index of hypertrophy” in STZ diabetic male Wistar rats. Shown also are the effects of DL-propargylglycine alone in non-diabetic and diabetic rats, and in combination with moxonidine (6 mg/kg/day) in diabetic rats.

Article Snippet: Drugs and Chemicals Moxonidine (American Custom Chemicals Corp., San Diego, CA), DL-propargylglycine (Chem-Impex International Inc., Wood Dale, IL), N,N dimethyl P-phenylene diamine sulfate (Acros Organics “Thermo Fischer Scientific”, Bridgewater, NJ), TEMED (Thermo scientific, Rockford, IL), Acrylamide 40% solution (Fischer Scientific, Pittsburg, PA), ammonium persulfate (J.T Baker, Center Valley, PA), heparin (Elkins Sinn Inc., Cherry Hill, NJ) and sterile saline (B. Braun Medical Inc., Bethlehem, PA) were purchased from commercial vendors.

Techniques:

Effect of 3-week treatment with moxonidine (2 or 6 mg/kg/day for 3 weeks; gavage; Mox 2 or Mox 6), administered 4 weeks after diabetes induction, on the glycemic control presented as glycemic tolerance (A) and, as area under glycemic curve (B) and on fasting blood glucose (C) and, in STZ diabetic male Wistar rats. Shown also are the effects of DL-propargylglycine, DLP (37.5 mg/kg/day; i.p) administered alone in non-diabetic (Con) or STZ-diabetic rats or in combination with moxonidine (6 mg/kg/day) in diabetic rats. Values are means ± S.E.M. (n=5–8 rats/group); * P <0.05 versus vehicle treated non-diabetic rats, # P <0.05 versus vehicle-treated diabetic rats, $ P<0.05 versus DL-propargylglycine treated nondiabetic rats and © P< 0.05 versus moxonidine (6 mg/kg) treated diabetic rats.

Journal: European journal of pharmacology

Article Title: Cystathionine-γ lyase-derived hydrogen sulfide mediates the cardiovascular protective effects of moxonidine in diabetic rats

doi: 10.1016/j.ejphar.2016.04.054

Figure Lengend Snippet: Effect of 3-week treatment with moxonidine (2 or 6 mg/kg/day for 3 weeks; gavage; Mox 2 or Mox 6), administered 4 weeks after diabetes induction, on the glycemic control presented as glycemic tolerance (A) and, as area under glycemic curve (B) and on fasting blood glucose (C) and, in STZ diabetic male Wistar rats. Shown also are the effects of DL-propargylglycine, DLP (37.5 mg/kg/day; i.p) administered alone in non-diabetic (Con) or STZ-diabetic rats or in combination with moxonidine (6 mg/kg/day) in diabetic rats. Values are means ± S.E.M. (n=5–8 rats/group); * P <0.05 versus vehicle treated non-diabetic rats, # P <0.05 versus vehicle-treated diabetic rats, $ P<0.05 versus DL-propargylglycine treated nondiabetic rats and © P< 0.05 versus moxonidine (6 mg/kg) treated diabetic rats.

Article Snippet: Drugs and Chemicals Moxonidine (American Custom Chemicals Corp., San Diego, CA), DL-propargylglycine (Chem-Impex International Inc., Wood Dale, IL), N,N dimethyl P-phenylene diamine sulfate (Acros Organics “Thermo Fischer Scientific”, Bridgewater, NJ), TEMED (Thermo scientific, Rockford, IL), Acrylamide 40% solution (Fischer Scientific, Pittsburg, PA), ammonium persulfate (J.T Baker, Center Valley, PA), heparin (Elkins Sinn Inc., Cherry Hill, NJ) and sterile saline (B. Braun Medical Inc., Bethlehem, PA) were purchased from commercial vendors.

Techniques:

Effects of 3-week treatment with moxonidine (2 or 6 mg/kg/day; gavage), starting 4 week following diabetes induction, on mean arterial pressure (MAP), heart rate (HR), and myocardial (LV +dp/dt) and baroreflex (BRS; Seq.”BRS-SAP” TOTAL) function in STZ diabetic male Wistar rats. Shown also are the effects of DL-propargylglycine alone in non-diabetic and diabetic rats and in combination with moxonidine (6 mg/kg/day) in diabetic rats.

Journal: European journal of pharmacology

Article Title: Cystathionine-γ lyase-derived hydrogen sulfide mediates the cardiovascular protective effects of moxonidine in diabetic rats

doi: 10.1016/j.ejphar.2016.04.054

Figure Lengend Snippet: Effects of 3-week treatment with moxonidine (2 or 6 mg/kg/day; gavage), starting 4 week following diabetes induction, on mean arterial pressure (MAP), heart rate (HR), and myocardial (LV +dp/dt) and baroreflex (BRS; Seq.”BRS-SAP” TOTAL) function in STZ diabetic male Wistar rats. Shown also are the effects of DL-propargylglycine alone in non-diabetic and diabetic rats and in combination with moxonidine (6 mg/kg/day) in diabetic rats.

Article Snippet: Drugs and Chemicals Moxonidine (American Custom Chemicals Corp., San Diego, CA), DL-propargylglycine (Chem-Impex International Inc., Wood Dale, IL), N,N dimethyl P-phenylene diamine sulfate (Acros Organics “Thermo Fischer Scientific”, Bridgewater, NJ), TEMED (Thermo scientific, Rockford, IL), Acrylamide 40% solution (Fischer Scientific, Pittsburg, PA), ammonium persulfate (J.T Baker, Center Valley, PA), heparin (Elkins Sinn Inc., Cherry Hill, NJ) and sterile saline (B. Braun Medical Inc., Bethlehem, PA) were purchased from commercial vendors.

Techniques:

Moxonidine (2 or 6 mg/kg/day for 3 weeks; gavage), administered 4 weeks after diabetes induction, ameliorated the diabetes-induced imidazoline I1 receptor upregulation (A), reductions in CSE expression (B) and activity (C) in the myocardium of STZ diabetic male Wistar rats. Shown also are the effects of DL-propargylglycine (37.5 mg/kg/day; i.p) administered alone in non-diabetic or diabetic male Wistar rats or in combination with moxonidine (6 mg/kg/day) in diabetic rats. Values are means ± S.E.M. (n=5–8 rats/group); * P <0.05 versus vehicle treated non-diabetic rats, # P <0.05 versus vehicle-treated diabetic rats, $ P<0.05 versus DL-propargylglycine treated nondiabetic rats and © P< 0.05 versus moxonidine (6 mg/kg) treated diabetic rats. Molecular weights of proteins were given in kDa, and splicing gel lanes was needed due to exclusion of some treatment groups from the study.

Journal: European journal of pharmacology

Article Title: Cystathionine-γ lyase-derived hydrogen sulfide mediates the cardiovascular protective effects of moxonidine in diabetic rats

doi: 10.1016/j.ejphar.2016.04.054

Figure Lengend Snippet: Moxonidine (2 or 6 mg/kg/day for 3 weeks; gavage), administered 4 weeks after diabetes induction, ameliorated the diabetes-induced imidazoline I1 receptor upregulation (A), reductions in CSE expression (B) and activity (C) in the myocardium of STZ diabetic male Wistar rats. Shown also are the effects of DL-propargylglycine (37.5 mg/kg/day; i.p) administered alone in non-diabetic or diabetic male Wistar rats or in combination with moxonidine (6 mg/kg/day) in diabetic rats. Values are means ± S.E.M. (n=5–8 rats/group); * P <0.05 versus vehicle treated non-diabetic rats, # P <0.05 versus vehicle-treated diabetic rats, $ P<0.05 versus DL-propargylglycine treated nondiabetic rats and © P< 0.05 versus moxonidine (6 mg/kg) treated diabetic rats. Molecular weights of proteins were given in kDa, and splicing gel lanes was needed due to exclusion of some treatment groups from the study.

Article Snippet: Drugs and Chemicals Moxonidine (American Custom Chemicals Corp., San Diego, CA), DL-propargylglycine (Chem-Impex International Inc., Wood Dale, IL), N,N dimethyl P-phenylene diamine sulfate (Acros Organics “Thermo Fischer Scientific”, Bridgewater, NJ), TEMED (Thermo scientific, Rockford, IL), Acrylamide 40% solution (Fischer Scientific, Pittsburg, PA), ammonium persulfate (J.T Baker, Center Valley, PA), heparin (Elkins Sinn Inc., Cherry Hill, NJ) and sterile saline (B. Braun Medical Inc., Bethlehem, PA) were purchased from commercial vendors.

Techniques: Expressing, Activity Assay

Moxonidine (2 or 6 mg/kg/day for 3 weeks; gavage), administered 4 weeks after diabetes induction, ameliorated the reductions in hydrogen sulfide (H2S) levels (A) and nitric oxide (NO) levels (B) in the myocardium of STZ diabetic male Wistar rats. Shown also are the effects of DL-propargylglycine (37.5 mg/kg/day; i.p) administered alone in non-diabetic or diabetic male Wistar rats or in combination with moxonidine (6 mg/kg/day) in diabetic rats. Values are means ± S.E.M. (n=5–8 rats/group); * P <0.05 versus vehicle treated non-diabetic rats, # P <0.05 versus vehicle-treated diabetic rats, $ P<0.05 versus DL-propargylglycine treated nondiabetic rats and © P< 0.05 versus moxonidine (6 mg/kg) treated diabetic rats.

Journal: European journal of pharmacology

Article Title: Cystathionine-γ lyase-derived hydrogen sulfide mediates the cardiovascular protective effects of moxonidine in diabetic rats

doi: 10.1016/j.ejphar.2016.04.054

Figure Lengend Snippet: Moxonidine (2 or 6 mg/kg/day for 3 weeks; gavage), administered 4 weeks after diabetes induction, ameliorated the reductions in hydrogen sulfide (H2S) levels (A) and nitric oxide (NO) levels (B) in the myocardium of STZ diabetic male Wistar rats. Shown also are the effects of DL-propargylglycine (37.5 mg/kg/day; i.p) administered alone in non-diabetic or diabetic male Wistar rats or in combination with moxonidine (6 mg/kg/day) in diabetic rats. Values are means ± S.E.M. (n=5–8 rats/group); * P <0.05 versus vehicle treated non-diabetic rats, # P <0.05 versus vehicle-treated diabetic rats, $ P<0.05 versus DL-propargylglycine treated nondiabetic rats and © P< 0.05 versus moxonidine (6 mg/kg) treated diabetic rats.

Article Snippet: Drugs and Chemicals Moxonidine (American Custom Chemicals Corp., San Diego, CA), DL-propargylglycine (Chem-Impex International Inc., Wood Dale, IL), N,N dimethyl P-phenylene diamine sulfate (Acros Organics “Thermo Fischer Scientific”, Bridgewater, NJ), TEMED (Thermo scientific, Rockford, IL), Acrylamide 40% solution (Fischer Scientific, Pittsburg, PA), ammonium persulfate (J.T Baker, Center Valley, PA), heparin (Elkins Sinn Inc., Cherry Hill, NJ) and sterile saline (B. Braun Medical Inc., Bethlehem, PA) were purchased from commercial vendors.

Techniques:

Moxonidine (2 or 6 mg/kg/day for 3 weeks; gavage), administered 4 weeks after diabetes induction, ameliorated the enhanced phosphorylation of p38 (A) and ERK1/2 (B) and suppressed DAPK3 expression (C) in STZ diabetic male Wistar rats. Shown also are the effects of DL-propargylglycine (37.5 mg/kg/day; i.p) administered alone in non-diabetic or diabetic male Wistar rats or in combination with moxonidine (6 mg/kg/day) in diabetic rats. Values are means ± S.E.M. (n=5–8 rats/group); * P <0.05 versus vehicle treated non-diabetic rats, # P <0.05 versus vehicle-treated diabetic rats, $ P<0.05 versus DL-propargylglycine treated nondiabetic rats and © P< 0.05 versus moxonidine (6 mg/kg) treated diabetic rats. Molecular weights of proteins were given in kDa, and representative blots for a particular protein in treatment and control groups were all run on the same gel; whenever the random order of the blots necessitated splicing gel lanes to present representative blots, this was identified by the gap in the presented blots.

Journal: European journal of pharmacology

Article Title: Cystathionine-γ lyase-derived hydrogen sulfide mediates the cardiovascular protective effects of moxonidine in diabetic rats

doi: 10.1016/j.ejphar.2016.04.054

Figure Lengend Snippet: Moxonidine (2 or 6 mg/kg/day for 3 weeks; gavage), administered 4 weeks after diabetes induction, ameliorated the enhanced phosphorylation of p38 (A) and ERK1/2 (B) and suppressed DAPK3 expression (C) in STZ diabetic male Wistar rats. Shown also are the effects of DL-propargylglycine (37.5 mg/kg/day; i.p) administered alone in non-diabetic or diabetic male Wistar rats or in combination with moxonidine (6 mg/kg/day) in diabetic rats. Values are means ± S.E.M. (n=5–8 rats/group); * P <0.05 versus vehicle treated non-diabetic rats, # P <0.05 versus vehicle-treated diabetic rats, $ P<0.05 versus DL-propargylglycine treated nondiabetic rats and © P< 0.05 versus moxonidine (6 mg/kg) treated diabetic rats. Molecular weights of proteins were given in kDa, and representative blots for a particular protein in treatment and control groups were all run on the same gel; whenever the random order of the blots necessitated splicing gel lanes to present representative blots, this was identified by the gap in the presented blots.

Article Snippet: Drugs and Chemicals Moxonidine (American Custom Chemicals Corp., San Diego, CA), DL-propargylglycine (Chem-Impex International Inc., Wood Dale, IL), N,N dimethyl P-phenylene diamine sulfate (Acros Organics “Thermo Fischer Scientific”, Bridgewater, NJ), TEMED (Thermo scientific, Rockford, IL), Acrylamide 40% solution (Fischer Scientific, Pittsburg, PA), ammonium persulfate (J.T Baker, Center Valley, PA), heparin (Elkins Sinn Inc., Cherry Hill, NJ) and sterile saline (B. Braun Medical Inc., Bethlehem, PA) were purchased from commercial vendors.

Techniques: Expressing

Immunohistochemical detection of Death Associated Protein Kinase-3 (DAPK-3) in ventricular myocytes of STZ-diabetic male Wistar rats treated with moxonidine (2 or 6 mg/kg/day for 3 weeks; gavage; Mox 2 or Mox 6), administered 4 weeks after diabetes induction. Shown also are the effects of DL-propargylglycine, DLP (37.5 mg/kg/day; i.p) administered alone in non-diabetic (Con) or STZ-diabetic male Wistar rats or in combination with moxonidine (6 mg/kg/day; Mox 6) in STZ-diabetic rats. Values are means ± S.E.M. (n=5–8 rats/group); * P<0.05 versus vehicle treated non-diabetic rats, # P<0.05 versus vehicle-treated diabetic rats.

Journal: European journal of pharmacology

Article Title: Cystathionine-γ lyase-derived hydrogen sulfide mediates the cardiovascular protective effects of moxonidine in diabetic rats

doi: 10.1016/j.ejphar.2016.04.054

Figure Lengend Snippet: Immunohistochemical detection of Death Associated Protein Kinase-3 (DAPK-3) in ventricular myocytes of STZ-diabetic male Wistar rats treated with moxonidine (2 or 6 mg/kg/day for 3 weeks; gavage; Mox 2 or Mox 6), administered 4 weeks after diabetes induction. Shown also are the effects of DL-propargylglycine, DLP (37.5 mg/kg/day; i.p) administered alone in non-diabetic (Con) or STZ-diabetic male Wistar rats or in combination with moxonidine (6 mg/kg/day; Mox 6) in STZ-diabetic rats. Values are means ± S.E.M. (n=5–8 rats/group); * P<0.05 versus vehicle treated non-diabetic rats, # P<0.05 versus vehicle-treated diabetic rats.

Article Snippet: Drugs and Chemicals Moxonidine (American Custom Chemicals Corp., San Diego, CA), DL-propargylglycine (Chem-Impex International Inc., Wood Dale, IL), N,N dimethyl P-phenylene diamine sulfate (Acros Organics “Thermo Fischer Scientific”, Bridgewater, NJ), TEMED (Thermo scientific, Rockford, IL), Acrylamide 40% solution (Fischer Scientific, Pittsburg, PA), ammonium persulfate (J.T Baker, Center Valley, PA), heparin (Elkins Sinn Inc., Cherry Hill, NJ) and sterile saline (B. Braun Medical Inc., Bethlehem, PA) were purchased from commercial vendors.

Techniques: Immunohistochemical staining

Amelioration by moxonidine (2 or 6 mg/kg/day for 3 weeks; gavage), administered 4 weeks after diabetes induction, of the reduction in serum adiponectin (A) and the elevations in plasma (B) and myocardial (C) malondialdehyde (MDA) in STZ diabetic male Wistar rats. Shown also are the effects of DL-propargylglycine (37.5 mg/kg/day; i.p) administered alone in non-diabetic or diabetic male Wistar rats or in combination with moxonidine (6 mg/kg/day) in diabetic rats. Values are means ± S.E.M. (n=5–8 rats/group); * P<0.05 versus vehicle treated non-diabetic rats, # P<0.05 versus vehicle-treated diabetic rats, $ P<0.05 versus DL-propargylglycine treated nondiabetic rats and © P< 0.05 versus moxonidine (6 mg/kg) treated diabetic rats.

Journal: European journal of pharmacology

Article Title: Cystathionine-γ lyase-derived hydrogen sulfide mediates the cardiovascular protective effects of moxonidine in diabetic rats

doi: 10.1016/j.ejphar.2016.04.054

Figure Lengend Snippet: Amelioration by moxonidine (2 or 6 mg/kg/day for 3 weeks; gavage), administered 4 weeks after diabetes induction, of the reduction in serum adiponectin (A) and the elevations in plasma (B) and myocardial (C) malondialdehyde (MDA) in STZ diabetic male Wistar rats. Shown also are the effects of DL-propargylglycine (37.5 mg/kg/day; i.p) administered alone in non-diabetic or diabetic male Wistar rats or in combination with moxonidine (6 mg/kg/day) in diabetic rats. Values are means ± S.E.M. (n=5–8 rats/group); * P<0.05 versus vehicle treated non-diabetic rats, # P<0.05 versus vehicle-treated diabetic rats, $ P<0.05 versus DL-propargylglycine treated nondiabetic rats and © P< 0.05 versus moxonidine (6 mg/kg) treated diabetic rats.

Article Snippet: Drugs and Chemicals Moxonidine (American Custom Chemicals Corp., San Diego, CA), DL-propargylglycine (Chem-Impex International Inc., Wood Dale, IL), N,N dimethyl P-phenylene diamine sulfate (Acros Organics “Thermo Fischer Scientific”, Bridgewater, NJ), TEMED (Thermo scientific, Rockford, IL), Acrylamide 40% solution (Fischer Scientific, Pittsburg, PA), ammonium persulfate (J.T Baker, Center Valley, PA), heparin (Elkins Sinn Inc., Cherry Hill, NJ) and sterile saline (B. Braun Medical Inc., Bethlehem, PA) were purchased from commercial vendors.

Techniques:

Suggested mechanisms for the improvement of cardiovascular function and glycemic control conferred by imidazoline I1 receptor activation in diabetic rats based on: (i) moxonidine ability to improve myocardial function (Table 2) and glycemic control (Fig. 2) along with reversing the reductions in myocardial cystathionine-γ lyase (CSE) expression/activity/H2S level (Figs. 3B, C and 5A) and circulating adiponectin (Fig. 8A); (ii) moxonidine-evoked suppression of Death Associated Protein Kinase-3 (DAPK-3) and mitogen activated protein kinase (MAPK) phosphorylation (Figs. 6, ​,7);7); (iii) abrogation by CSE inhibition (DL-propargylglycine) of the aforementioned biochemical events and the favorable cardiovascular effects and glycemic control elicited by moxonidine in diabetic rats (see text for details).

Journal: European journal of pharmacology

Article Title: Cystathionine-γ lyase-derived hydrogen sulfide mediates the cardiovascular protective effects of moxonidine in diabetic rats

doi: 10.1016/j.ejphar.2016.04.054

Figure Lengend Snippet: Suggested mechanisms for the improvement of cardiovascular function and glycemic control conferred by imidazoline I1 receptor activation in diabetic rats based on: (i) moxonidine ability to improve myocardial function (Table 2) and glycemic control (Fig. 2) along with reversing the reductions in myocardial cystathionine-γ lyase (CSE) expression/activity/H2S level (Figs. 3B, C and 5A) and circulating adiponectin (Fig. 8A); (ii) moxonidine-evoked suppression of Death Associated Protein Kinase-3 (DAPK-3) and mitogen activated protein kinase (MAPK) phosphorylation (Figs. 6, ​,7);7); (iii) abrogation by CSE inhibition (DL-propargylglycine) of the aforementioned biochemical events and the favorable cardiovascular effects and glycemic control elicited by moxonidine in diabetic rats (see text for details).

Article Snippet: Drugs and Chemicals Moxonidine (American Custom Chemicals Corp., San Diego, CA), DL-propargylglycine (Chem-Impex International Inc., Wood Dale, IL), N,N dimethyl P-phenylene diamine sulfate (Acros Organics “Thermo Fischer Scientific”, Bridgewater, NJ), TEMED (Thermo scientific, Rockford, IL), Acrylamide 40% solution (Fischer Scientific, Pittsburg, PA), ammonium persulfate (J.T Baker, Center Valley, PA), heparin (Elkins Sinn Inc., Cherry Hill, NJ) and sterile saline (B. Braun Medical Inc., Bethlehem, PA) were purchased from commercial vendors.

Techniques: Activation Assay, Expressing, Activity Assay, Inhibition

Immunohistochemical detection of cystathionine-γ lyase (CSE) in ventricular myocytes of STZ-diabetic male Wistar rats treated with moxonidine (2 or 6 mg/kg/day for 3 weeks; gavage; Mox 2 or Mox 6), administered 4 weeks after diabetes induction. Shown also are the effects of DL-propargylglycine, DLP (37.5 mg/kg/day; i.p) administered alone in non-diabetic (Con) or STZ-diabetic male Wistar rats or in combination with moxonidine (6 mg/kg/day) in STZ-diabetic rats. Values are means ± S.E.M. (n=5–8 rats/group); * P <0.05 versus vehicle treated non-diabetic rats.

Journal: European journal of pharmacology

Article Title: Cystathionine-γ lyase-derived hydrogen sulfide mediates the cardiovascular protective effects of moxonidine in diabetic rats

doi: 10.1016/j.ejphar.2016.04.054

Figure Lengend Snippet: Immunohistochemical detection of cystathionine-γ lyase (CSE) in ventricular myocytes of STZ-diabetic male Wistar rats treated with moxonidine (2 or 6 mg/kg/day for 3 weeks; gavage; Mox 2 or Mox 6), administered 4 weeks after diabetes induction. Shown also are the effects of DL-propargylglycine, DLP (37.5 mg/kg/day; i.p) administered alone in non-diabetic (Con) or STZ-diabetic male Wistar rats or in combination with moxonidine (6 mg/kg/day) in STZ-diabetic rats. Values are means ± S.E.M. (n=5–8 rats/group); * P <0.05 versus vehicle treated non-diabetic rats.

Article Snippet: Drugs and Chemicals Moxonidine (American Custom Chemicals Corp., San Diego, CA), DL-propargylglycine (Chem-Impex International Inc., Wood Dale, IL), N,N dimethyl P-phenylene diamine sulfate (Acros Organics “Thermo Fischer Scientific”, Bridgewater, NJ), TEMED (Thermo scientific, Rockford, IL), Acrylamide 40% solution (Fischer Scientific, Pittsburg, PA), ammonium persulfate (J.T Baker, Center Valley, PA), heparin (Elkins Sinn Inc., Cherry Hill, NJ) and sterile saline (B. Braun Medical Inc., Bethlehem, PA) were purchased from commercial vendors.

Techniques: Immunohistochemical staining